Is entrectinib a targeted drug or a chemotherapy drug?

Entrectinib is a targeted therapy drug rather than a traditional chemotherapy drug. Targeted therapy drugs are drugs that act on specific molecular targets or signaling pathways in tumor cells. Compared with traditional chemotherapy drugs, targeted drugs have higher selectivity and fewer side effects.

Enrectinib mainly acts on tumors carrying NTRK gene fusion mutations and ROS1 positive non-small cell lung cancer (NSCLC). In these specific types of cancer, there are abnormal molecular changes in the tumor cells, such as proteins formed by the fusion of the NTRK gene with other genes or proteins formed by the fusion of the ROS1 gene. These abnormal molecular changes promote the growth and spread of tumor cells.

The mechanism of action of entrectinib is to inhibit the proliferation and survival of tumor cells by specifically interfering with the activity of these abnormal signaling pathways. It blocks the activity of these proteins by binding to NTRK gene fusion proteins or ROS1 proteins, thereby inhibiting the development of tumors.

Compared with traditional chemotherapy drugs, targeted therapy drugs such as entrectinib are more specific and only act on abnormal signaling pathways in tumor cells, reducing damage to normal cells, thereby reducing the occurrence of many side effects. In addition, targeted drugs are generally better tolerated and less resistant.

In summary, entrectinib is a targeted therapy that inhibits the growth and spread of tumor cells carrying specific gene fusion mutations by specifically interfering with abnormal signaling pathways. It has higher specificity, fewer side effects, and better tolerability than traditional chemotherapy drugs, so it is widely used in the treatment of certain types of cancer.